Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

Novo Nordisk's hemophilia A drug Mim8 shows success in pediatric trial, Mim8 could compete with Roche's Hemlibra, with plans ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...